Summary
Yeast cells have been engineered to express mixed HBsAg particles containing the S and a modified large (L*) protein. Their construc¬tion resulted in reduced protease sensitivity, reduced glycosylation and complete inactivation of the polymerized human albumin binding site. The particles exposed the S, preSl and preS2 antigenic determinants and induced an immune response against the three domains. Highly purified preparations have been obtained and are presently being tested in human volunteers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alberti A, Pontisso P (1987) Antibody to preS antigens in hepatitis B virus infection. Hepatology 7: 207–208
André FE, Safary A (1988) Clinical experience with a yeast-derived hepatitis B vaccine. In: Zuckerman AJ (ed) Viral hepatitis and liver disease. Liss, New York, pp 1025–1030
Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F (1990) Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 345: 258–260
Ferrari C, Penna A, Bertoletti A, Cavalli A, Valli A, Schianchi C, Fiaccadori F (1989) The preSl antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest 84: 1314–1319
Gerety RJ (1988) Recombinant hepatitis B vaccines. In: Zuckerman AJ (ed) Viral hepatitis and liver disease. Liss, New York, pp 1017–1024
Harford N, Cabezon T, Crabeel M, Simoen E, Rutgers A, De Wilde M (1983) Expression of hepatitis B surface antigen in yeast. Dev Biol Stand 54: 125–130
Heermann KH, Goldmann V, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH
Large surface proteins of hepatitis B virus containing the preS sequence. J Virol 52: 396–402
Hellström U, Sylvan S (1986) Human serum albumin and the enigma of chronic hepatitis type B. Scand J Immunol 23: 523–527
Iwarson S, Tabor E, Thomas HC, Goodall A, Waters J, Snoy P, Shih JWK, Gerety RJ
Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody. An experimental study in chimpanzee. J Med Virol 16: 89–96
Milich DR, Mc Lachlan A, Chisari FV, Kent BH, Thornton GB (1986) Immune response to the pre-S(l) region of the hepatitis B surface antigen (HBsAg): a pre-S(l) specific T cell response can bypass non responsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 137: 315–322
Milich DR, Mc Namara MK, Mc Lachlan A, Thornton GB, Chisari FV (1985) Distinct H-2 linked regulation of T-cell responses to pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of non responsiveness to the S region. Proc Natl Acad Sci USA 82: 8168–8172
Neurath AR, Seto B, Strick N (1989) Antibodies to synthetic peptides from the preSl region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 7: 234–236
Petit M-A, Dubanchet S, Capel F (1989) A monoclonal antibody specific for the hepatocyte receptor binding site on hepatitis B virus. Mol Immunol 26: 531–537
Waters J, Pignatelli M, Galpin S, Ishihara K, Thomas HC (1986) Virus neutralizing antibodies to hepatitis B: the nature of an immunogenic epitope on the S gene peptide. J Gen Virol 67: 2467–2473
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag
About this paper
Cite this paper
Petre, J., Rutgers, T., Hauser, P. (1992). Properties of a recombinant yeast-derived hepatitis B surface antigen containing S, preS2 and preSl antigenic domains. In: De Bac, C., Taliani, G., Gerlich, W.H. (eds) Chronically Evolving Viral Hepatitis. Archives of Virology, vol 4. Springer, Vienna. https://doi.org/10.1007/978-3-7091-5633-9_30
Download citation
DOI: https://doi.org/10.1007/978-3-7091-5633-9_30
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82350-7
Online ISBN: 978-3-7091-5633-9
eBook Packages: Springer Book Archive